Northern Trust Corp purchased a new position in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 143,721 shares of the company's stock, valued at approximately $2,363,000. Northern Trust Corp owned about 0.27% of Upstream Bio as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. US Bancorp DE purchased a new position in Upstream Bio in the fourth quarter worth about $27,000. Legal & General Group Plc purchased a new position in Upstream Bio in the 4th quarter worth approximately $28,000. Summit Investment Advisors Inc. purchased a new position in Upstream Bio in the 4th quarter worth approximately $30,000. Tower Research Capital LLC TRC bought a new position in Upstream Bio in the 4th quarter valued at approximately $47,000. Finally, Corebridge Financial Inc. purchased a new stake in Upstream Bio during the 4th quarter valued at $142,000.
Upstream Bio Stock Down 3.8%
Shares of Upstream Bio stock traded down $0.35 on Friday, reaching $9.00. The company's stock had a trading volume of 88,701 shares, compared to its average volume of 283,758. Upstream Bio, Inc. has a 52 week low of $5.14 and a 52 week high of $29.46. The firm's fifty day simple moving average is $8.15 and its two-hundred day simple moving average is $11.98.
Upstream Bio (NASDAQ:UPB - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.02). The firm had revenue of $0.57 million for the quarter, compared to analysts' expectations of $0.71 million. Equities analysts predict that Upstream Bio, Inc. will post -4.3 EPS for the current fiscal year.
About Upstream Bio
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
See Also
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
